226 related articles for article (PubMed ID: 11342630)
1. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.
McCall AM; Shahied L; Amoroso AR; Horak EM; Simmons HH; Nielson U; Adams GP; Schier R; Marks JD; Weiner LM
J Immunol; 2001 May; 166(10):6112-7. PubMed ID: 11342630
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
[TBL] [Abstract][Full Text] [Related]
3. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
[TBL] [Abstract][Full Text] [Related]
4. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
6. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
[TBL] [Abstract][Full Text] [Related]
7. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
Tang Y; Lou J; Alpaugh RK; Robinson MK; Marks JD; Weiner LM
J Immunol; 2007 Sep; 179(5):2815-23. PubMed ID: 17709495
[TBL] [Abstract][Full Text] [Related]
8. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
9. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
10. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
11. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
Xie Z; Guo N; Yu M; Hu M; Shen B
J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
[TBL] [Abstract][Full Text] [Related]
12. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.
Xie Z; Shi M; Feng J; Yu M; Sun Y; Shen B; Guo N
Biochem Biophys Res Commun; 2003 Nov; 311(2):307-12. PubMed ID: 14592414
[TBL] [Abstract][Full Text] [Related]
13. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
16. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16.
Lu H; Shi M; Wang M; Xie Z; Hu M; Yu M; Shen B; Ma Y; Guo N
Cancer Biol Ther; 2008 Nov; 7(11):1744-50. PubMed ID: 18787406
[TBL] [Abstract][Full Text] [Related]
18. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
19. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
[TBL] [Abstract][Full Text] [Related]
20. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]